Assessment of quality of life, pain, depression, and body-image in breast cancer patients in neoadjuvant therapy.

Breast cancer is the leading cancer type among women globally, and its chemotherapy often results in multiple side effects, compromising the patient's quality of life. Our study aimed to analyze the impact of neoadjuvant chemotherapy on the quality of life in Brazilian women with breast cancer within the public health system. This research was a one-year, observational, longitudinal study, conducted at a charitable health facility, examining the effect of neoadjuvant chemotherapy on these women's quality of life. Sociodemographic and clinical data were extracted from medical records. Quality of life parameters were gauged using Portuguese-validated questionnaires: EORTC.QLQ - C30 version 3.0, EORTC.BR-23, Body Image Scale (BIS), BPI-SF pain scale, and Beck Depression Inventory (BDI). These tools were utilized at three intervals: before the start of systemic treatment, after three months (before initiating paclitaxel), and upon concluding neoadjuvant therapy. Qualitative variables were tested for normality using the Kolmogorov-Smirnov test. As the continuous variables referring to the questionnaires did not show normal distribution, non-parametric tests were used: Friedman tests for paired pairs, and Wilcoxon and Mann-Whitney tests for multiple comparisons. In all tests, the significance level adopted was 5%. The software used for the analysis was SPSS. Our findings revealed a decline in quality of life, observing deterioration in the role, social, and cognitive functioning domains. Additionally, symptoms like fatigue, hyporexia, constipation, and diarrhea became more pronounced during the treatment. The presence of minimal depressive symptoms, associated with systemic therapy side effects also contributed to this worsening. Notably, there were no improvements in any quality of life-related parameters, and no discernible differences were observed in pain levels or body image across the evaluated periods.